HUT64514A - Process for producing arylic comdounds with anti-atherosclerotic effect - Google Patents

Process for producing arylic comdounds with anti-atherosclerotic effect Download PDF

Info

Publication number
HUT64514A
HUT64514A HU9301709A HU170993A HUT64514A HU T64514 A HUT64514 A HU T64514A HU 9301709 A HU9301709 A HU 9301709A HU 170993 A HU170993 A HU 170993A HU T64514 A HUT64514 A HU T64514A
Authority
HU
Hungary
Prior art keywords
alkyl
alkoxy
methyl
group
atoms
Prior art date
Application number
HU9301709A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9301709D0 (en
Inventor
Karl Witold Franzmann
Kevin Julian O'connor
Roy Lee Hawke
James Mood Chapman
Original Assignee
Wellcome Found
Univ South Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found, Univ South Carolina filed Critical Wellcome Found
Publication of HU9301709D0 publication Critical patent/HU9301709D0/hu
Publication of HUT64514A publication Critical patent/HUT64514A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Indole Compounds (AREA)
HU9301709A 1990-12-12 1991-12-11 Process for producing arylic comdounds with anti-atherosclerotic effect HUT64514A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027023A GB9027023D0 (en) 1990-12-12 1990-12-12 Anti-atherosclerotic aryl compounds

Publications (2)

Publication Number Publication Date
HU9301709D0 HU9301709D0 (en) 1993-09-28
HUT64514A true HUT64514A (en) 1994-01-28

Family

ID=10686924

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9301709A HUT64514A (en) 1990-12-12 1991-12-11 Process for producing arylic comdounds with anti-atherosclerotic effect

Country Status (16)

Country Link
US (1) US5658944A (OSRAM)
EP (1) EP0639178B1 (OSRAM)
JP (1) JP2951402B2 (OSRAM)
KR (1) KR930703246A (OSRAM)
AT (1) ATE157651T1 (OSRAM)
AU (1) AU647859B2 (OSRAM)
CA (1) CA2098122C (OSRAM)
DE (1) DE69127556D1 (OSRAM)
GB (1) GB9027023D0 (OSRAM)
HU (1) HUT64514A (OSRAM)
IE (1) IE914304A1 (OSRAM)
IL (1) IL100331A (OSRAM)
NZ (1) NZ240935A (OSRAM)
TW (1) TW275065B (OSRAM)
WO (1) WO1992010468A1 (OSRAM)
ZA (1) ZA919773B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe
SE9401353D0 (sv) * 1994-04-21 1994-04-21 Pharmacia Ab Novel antitumour compounds with antimitotic activity
HRP950558A2 (en) * 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
DE4443891A1 (de) * 1994-12-09 1996-06-13 Bayer Ag Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5866609A (en) * 1996-08-09 1999-02-02 Ss Pharmaceutical Co., Ltd. Substituted vinylurea derivatives and medicine containing the same
HRP20010785A2 (en) * 1999-04-28 2003-02-28 Reddys Lab Ltd Dr Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
WO2002014291A1 (fr) 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. ACTIVATEURS DE PPAR$G(d)
JPWO2002046176A1 (ja) * 2000-12-05 2004-04-08 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
BR0207227A (pt) * 2001-02-15 2004-02-10 Pfizer Prod Inc Compostos receptores ativados proliferadores ppar
WO2002064549A1 (en) * 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
US6548538B2 (en) * 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
US20030125338A1 (en) * 2001-06-12 2003-07-03 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
US20030191144A1 (en) * 2001-06-12 2003-10-09 Active Pass Pharmaceuticals, Inc. Compounds, compositions and methods for modulating beta-amyloid production
ES2372813T3 (es) 2001-08-10 2012-01-26 Nippon Chemiphar Co., Ltd. Activador del receptor delta sensible a proliferadores de peroxisomas.
IL161351A0 (en) 2001-10-12 2004-09-27 Nippon Chemiphar Co ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR delta
US7015345B2 (en) * 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
BR0311834A (pt) 2002-06-19 2005-04-12 Lilly Co Eli Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
EP1388352A1 (en) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
ATE430728T1 (de) 2002-10-21 2009-05-15 Janssen Pharmaceutica Nv Substituierte tetraline und indane und ihre verwendung
CA2507465C (en) * 2002-11-26 2009-04-28 Pfizer Products Inc. Phenyl substituted piperidine compounds for use as ppar activators
AU2004206860B2 (en) 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070161617A1 (en) 2005-12-15 2007-07-12 Morgan Bradley P Certain chemical entities, compositions and methods
EP1959962A2 (en) 2005-12-16 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
DK2014652T3 (da) 2006-04-18 2014-10-13 Nippon Chemiphar Co Aktiveringsmiddel til peroxisom-proliferator-aktiveret receptor
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
US9187411B2 (en) 2012-01-10 2015-11-17 Eli Lilly And Company Leukotriene B4 antagonist compound
WO2013169648A1 (en) 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614045A1 (de) * 1976-04-01 1977-10-06 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben
US4397868A (en) * 1982-01-26 1983-08-09 American Cyanamid Company Method of treating atherosclerosis with trisubstituted ureas
US4387106A (en) * 1982-01-26 1983-06-07 American Cyanamid Company Method of treating atherosclerosis with di(aralkyl)ureas and di(aralkyl)thioureas
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
WO1988010113A1 (en) * 1987-06-15 1988-12-29 Iraj Lalezari Compound, composition and method for the reduction of lipids the modification of the affinity of hemoglobin for oxygen and the prevention of platelet aggregation
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
GB8827152D0 (en) * 1988-11-21 1988-12-29 Wellcome Found Anti-atherosclerotic diaryl compounds

Also Published As

Publication number Publication date
AU647859B2 (en) 1994-03-31
GB9027023D0 (en) 1991-01-30
HU9301709D0 (en) 1993-09-28
US5658944A (en) 1997-08-19
AU9056091A (en) 1992-07-08
KR930703246A (ko) 1993-11-29
CA2098122C (en) 2003-09-23
ZA919773B (en) 1993-06-11
ATE157651T1 (de) 1997-09-15
WO1992010468A1 (en) 1992-06-25
IL100331A (en) 1996-09-12
EP0639178A1 (en) 1995-02-22
CA2098122A1 (en) 1992-06-13
IE914304A1 (en) 1992-06-17
JP2951402B2 (ja) 1999-09-20
JPH06507151A (ja) 1994-08-11
DE69127556D1 (de) 1997-10-09
IL100331A0 (en) 1992-09-06
EP0639178B1 (en) 1997-09-03
NZ240935A (en) 1994-11-25
TW275065B (OSRAM) 1996-05-01

Similar Documents

Publication Publication Date Title
HUT64514A (en) Process for producing arylic comdounds with anti-atherosclerotic effect
HU184959B (en) Process for producing new amino-ethanel derivatives
LU85856A1 (fr) Composes de phenethanolamine
PL154186B1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
FR2536749A1 (fr) (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique
FR2491467A1 (fr) Nouveaux n-alkyl inferieur)-3-phenoxy-1-azetidinecarboxamides possedant notamment une activite sur le systeme nerveux central, et leur procede de preparation
FR2527204A1 (fr) Nouveaux composes utiles comme medicaments anti-allergiques et procede et intermediaires pour leur separation
LU86002A1 (fr) Composes d'aminophenol
DE2332837A1 (de) Amine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
EP0051077A1 (de) Substituierte Oxocarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
EP1001944B1 (fr) Derives de pyrazine, leur preparation et les medicaments les contenant
US5422373A (en) Anti-atherosclerotic aryl compounds
FR2461699A1 (fr) Nouveaux derives de type methylene-3 azetidine utiles comme medicaments et compositions therapeutiques les contenant
EP0143016B1 (fr) Dérivés de 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-N-phényl acétamide, leur préparation et leur application en thérapeutique
US3856951A (en) Substituted benzoic acid hypoliphemic agents
CH646425A5 (fr) Composes heterocycliques azotes therapeutiquement actifs, et medicament les contenant.
JPS6270335A (ja) ２環性アリルエ−テル誘導体、その製法および用途
HK123396A (en) New bronchospasmolytic compounds and process for their preparation
JPH06503839A (ja) 経口活性抗ウィルス化合物
JPH02292213A (ja) 制癌剤
FR2690917A1 (fr) Aminoesters, leur procédé de préparation et leur application en thérapeutique.
FR2632641A1 (fr) ((aryl-4-piperazinyl-1)-2 ethoxy)-3 p-cymene, les derives ortho, meta, para monosubstitues ou disubstitues sur le noyau phenyle dudit produit, le procede de preparation desdits derives, et les medicaments contenant lesdits composes comme principe actif
FR2544313A1 (fr) Les n-cycloalcoyl methyl-2 oxo-3 diaryl 5-6 as triazines, leur procede de fabrication et leur utilisation en tant que medicament
US4124706A (en) Esters of bis-(hydroxyalkylthio)-alkanes
US4024259A (en) 3-Anilino-2,4-diazabicyclo[3.2.1]octenes

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal